6996 Overzicht aandelen Antengene Corporation Limited, een biofarmaceutisch bedrijf, houdt zich bezig met de ontwikkeling van nieuwe oncologische therapieën in Groot-China en internationaal. Meer informatie
Beloningen Risicoanalyse Alle risicocontroles bekijken Leg je gedachten, links en bedrijfsverhaal vast
Antengene Corporation Limited Concurrenten Prijsgeschiedenis en prestaties
Overzicht van hoogtepunten, dieptepunten en veranderingen in de aandelenkoersen voor Antengene Historische aandelenkoersen Huidige aandelenkoers HK$0.63 52 Week Hoogtepunt HK$2.00 52 Week Laag HK$0.50 Bèta 0.73 1 maand verandering -4.55% 3 maanden verandering 6.78% 1 Jaar Verandering -62.05% 3 jaar verandering -93.47% 5 jaar verandering n/a Verandering sinds IPO -96.55%
Recent nieuws en updates
Antengene Corporation Limited Announces Xpovio's New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to Dlbcl Patients in the Country Nov 28
South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO Oct 18
First half 2024 earnings: EPS and revenues exceed analyst expectations Sep 30
Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications Sep 23
New minor risk - Share price stability Sep 17
Consensus revenue estimates decrease by 32%, EPS upgraded Aug 30 Meer updates bekijken
Antengene Corporation Limited Announces Xpovio's New Indication Included in 2024 China National Reimbursement Drug List, Making the Drug More Accessible to Dlbcl Patients in the Country Nov 28
South Korean Ministry of Food and Drug Safety Approves Supplemental New Drug Application for Antengene Corporation Limited's XPOVIO Oct 18
First half 2024 earnings: EPS and revenues exceed analyst expectations Sep 30
Antengene Corporation Limited Announces Approval of NDA by the Thailand Food and Drug Administration for Xpovio for Two Indications Sep 23
New minor risk - Share price stability Sep 17
Consensus revenue estimates decrease by 32%, EPS upgraded Aug 30
First half 2024 earnings: EPS and revenues exceed analyst expectations Aug 27
Antengene Corporation Limited to Report First Half, 2024 Results on Aug 23, 2024 Aug 01
Antengene Corporation Limited Announces Resignation of John F. Chin as Executive Director and Chief Business Officer, Effective August 1, 2024 Jul 31
Antengene Corporation Limited Announces China National Medical Products Administration Approves New Indication in DLBCL in China, Bringing A New Treatment Option to Patients in the Country Jul 06
Consensus revenue estimates decrease by 63%, EPS upgraded Mar 29
Antengene Corporation Limited, Annual General Meeting, Jun 14, 2024 Mar 23
Full year 2023 earnings: EPS and revenues miss analyst expectations Mar 23
Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study Mar 20
Antengene Corporation Limited to Report Fiscal Year 2023 Results on Mar 22, 2024 Mar 12
Consensus revenue estimates decrease by 24%, EPS upgraded Jan 11
Revenues Tell The Story For Antengene Corporation Limited (HKG:6996) Jan 09
Antengene Corporation Limited Announces Successfully Included in 2023 National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Dec 14
Antengene Corporation Limited Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031 Dosed Its First Patient in the United States Dec 11
Antengene Announces Xpovio Regulatory Approval in Macau for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Dec 06
Antengene Corporation Limited Presents Encouraging Clinical Data from Four Pipeline Programs at the 2023 R&D Day Nov 17
Antengene Corporation Limited Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031 Sep 22
The Price Is Right For Antengene Corporation Limited (HKG:6996) Even After Diving 26% Sep 20
New minor risk - Shareholder dilution Sep 20
Consensus revenue estimates decrease by 16%, EPS upgraded Sep 06
First half 2023 earnings released: CN¥0.36 loss per share (vs CN¥0.23 loss in 1H 2022) Aug 26
Antengene Corporation Limited to Report First Half, 2023 Results on Aug 25, 2023 Aug 16
Antengene Corporation Limited Announces Xpovio Regulatory Approval in Hong Kong for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Jul 17
New minor risk - Share price stability Jul 07
Antengene Announces Xpovio Plus Bortezomib and Dexamethasone Included for Reimbursement by the Pbs in Australia for the Treatment of Relapsed And/Or Refractory Multiple Myeloma Jun 03
Antengene Corporation Limited Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers May 24
Antengene Corporation Limited Announces Clearance of U.S. IND for the Phase I Trial of First-in-Class Anti-CD24 Monoclonal Antibody ATG-031 May 18
Antengene Corporation Limited (HKG:6996) Analysts Just Slashed This Year's Estimates Apr 03
We're Not Very Worried About Antengene's (HKG:6996) Cash Burn Rate Feb 19
Antengene Corporation Limited Announces Executive Changes Dec 07
Antengene Corporation Limited Highlights Encouraging Atg-008 Efficacy Results from Torch-2 Study in Combination with Pd-1 Antibody in Relapsed/Metastatic Cervical Cancer Nov 16
Less than half of directors are independent Nov 16
Preliminary Results from Two Clinical Studies of Selinexor to Be Presented At 2022 Ash Annual Meeting Nov 08
Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth Nov 05
Antengene Corporation Limited Announces Approval for the Phase I Stamina-001 Study Toevaluate Atg-037 Nov 03
Antengene Corporation Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors Nov 01
Antengene Corporation Limited Announces Approval in Taiwan for Atg-010 (Selinexor) for Thetreatment of Relapsed And/Or Refractory Multiplemyeloma and Diffuse Large B-Cell Lymphoma Oct 22
First half 2022 earnings released: CN¥0.23 loss per share (vs CN¥0.37 loss in 1H 2021) Sep 02
Antengene Corporation Limited Announces First Patient Dosed in the PROBE-CN Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma Aug 03 Antengene Corporation Limited to Report First Half, 2022 Results on Aug 30, 2022
We Think Antengene (HKG:6996) Can Afford To Drive Business Growth Jun 28
Antengene Corporation Limited Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors Jun 08
Antengene Corporation Limited Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule ATR Inhibitor ATG-018 Jun 07
Antengene Announces First Patient Dosed in the Phase I Stamina-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors May 31
Antengene Corporation Limited Announces First Patient Dosed in the Phase I/II SWATCH Study of XPOVIO® (Selinexor) for the Treatment of B-Cell Non-Hodgkin Lymphomas May 23
Antengene Corporation Limited Announces That the Uses of XPOVIO®(Selinexor) for Multiple Myeloma Patients with First Relapse or Multiple Relapses Were Incorporated into the Guidelines for the Diagnosis and Management of Multiple Myeloma in China May 19
Antengene Corporation Limited Announces Commercial Availability of Xpovio(R) (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China May 18
Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China May 16
Antengene Announces XPOVIO® (selinexor) Data to be Presented at the Upcoming 2022 European Hematology Association Hybrid Congress May 14
Antengene Corporation Limited Announces Submission to the Human Research Ethics Committee in Australia for A Phase I Trial of ATG-018 Apr 27
Less than half of directors are independent Apr 27
Antengene Corporation Limited Announces Pivotal "March" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine Apr 07
Antengene Corporation Limited Announces Management Changes Mar 31
Antengene Corporation Limited Announces the China National Medical Products Administration Approve A Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes Mar 30
We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely Mar 08 Antengene Announces Xpovio® Regulatory Approval in Singapore for the Treatment of Relapsed And/Or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037 Feb 07
Antengene Corporation Limited Announces First Patient Dosed in REACH Study of ATG-016 for the Treatment of Advanced Solid Tumors Dec 30
Antengene Corporation Limited announces First Patient Dose in Australia in ATG-101 First-in-Human Trial Dec 20
National Medical Products Administration Grants Marketing Approval for Antengene Corporation Limited's Selinexor(Atg-010) in China Dec 18
Antengene Presents Results of Phase 1b Touch Trial of Selinexor for the Treatment of T and NK-Cell Lymphoma At the 2021 American Society of Hematology (ASH) Annual Meeting Dec 15
Antengene Announces Clinical Collaboration with Bristol Myers Squibb to Evaluate ATG-017 in Combination with Opdivo® (nivolumab) in Advanced Solid Tumors Dec 13
We're Hopeful That Antengene (HKG:6996) Will Use Its Cash Wisely Nov 18
Antengene Corporation Limited Announces Approval of the Phase II Study of Selinexor for the Treatment of Myelofibrosis in China Aug 24
Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth Aug 17
Antengene Announces The Approval by Human Research Ethics Committeein Australia and to Start the Phase 1 Trial of ATG-101 (the first PD-L1/4-1BB bispecific antibody) in Solid Tumors and Non-Hodgkin Lymphoma Jul 23
Antengene Announces Acceptance of IND Application in China for the Phase II Clinical Trial of Single-Agent Selinexor for the Treatment of Myelofibrosis (MF) Jul 07
Non-Executive Director Zhen Li has left the company Jun 24
Non-Executive Director Zhen Li has left the company Jun 23
Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021 Jun 04
Antengene Corporation Limited Announces First Patient Dosed in Phase I/II Trial of Eltanexor for the Treatment of Myelodysplastic Syndrome May 28
Antengene Corporation Limited Announces the Completion of the Quantitative and Systems Pharmacology Modeling for ATG-101 in Preparation for First-in-Human Trial May 17
Antengene Corporation Limited Receives the Approval of the Investigational New Drug Application by the National Medical Products Administration May 15
Antengene Corporation Limited Announces the Completion of Its Manufacturing Center in Shaoxing to Accelerate the Commercialization of Novel Anti-Cancer Therapies May 14
Antengene Corporation Limited Announces IND Approval in China for a Global Phase III Trial of Selinexor in Advanced or Recurrent Endometrial Cancer May 13
Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines May 07
Companies Like Antengene (HKG:6996) Are In A Position To Invest In Growth Apr 29
Non-Executive Director has left the company Mar 27
Antengene Appoints Minyoung Kim as General Manager of Antengene South Korea Mar 15
New 90-day low: HK$15.24 Mar 08
Antengene Corporation Limited to Report Fiscal Year 2020 Results on Mar 25, 2021 Mar 06
Antengene Corporation Limited Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA Feb 25
What Type Of Shareholders Own The Most Number of Antengene Corporation Limited (HKG:6996) Shares? Feb 22
Antengene Corporation Limited Announces Collaboration with WuXi Biologics and WuXi STA to Advance Antibody-Drug Conjugate Candidate into Clinical-stage Feb 01
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM Jan 29
Antengene Corporation Limited Announces Approval of IND Application in China for ATG-010 (Selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study Jan 26
Antengene Corporation Limited Announces Submission of IND Application in China for a Global Phase 3 Trial of ATG-010 (Selinexor) in Advanced or Recurrent Endometrial Cancer Jan 05
Antengene Corporation Limited Submits NDA for ATG-010 (Selinexor) in South Korea for rrMM and rrDLBCL Jan 04
National Medical Products Administration Approves the Investigational New Drug Application for Antengene Corporation Limited's ATG-010 Dec 20
Antengene Corporation Limited Announces Acceptance of IND Application in China for A Phase 3 Clinical Trial of Atg-010 (Selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of rrMM Dec 12
Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology Dec 10
Antengene Corporation Limited Announces Acceptance of IND Application in China for ATG-010 (selinexor) in Combination with R-GDP (SR-GDP) for the Treatment of rrDLBCL in a Global Phase 2/3 Study Dec 09 Rendement voor aandeelhouders 6996 HK Pharmaceuticals HK Markt 7D 3.3% -1.9% -0.5% 1Y -62.0% -3.9% 19.9%
Bekijk het volledige aandeelhoudersrendement
Rendement versus industrie: 6996 presteerde slechter dan de Hong Kong Pharmaceuticals -sector, die het afgelopen jaar een rendement van -3.9 % opleverde.
Rendement versus markt: 6996 presteerde slechter dan Hong Kong Market , dat het afgelopen jaar een rendement van 19.9 % opleverde.
Prijsvolatiliteit Is 6996's price volatile compared to industry and market? 6996 volatility 6996 Average Weekly Movement 18.4% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.6% 10% least volatile stocks in HK Market 4.1%
Stabiele aandelenkoers: De aandelenkoers van 6996 is de afgelopen 3 maanden volatiel geweest.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van 6996 is het afgelopen jaar gestegen van 12% naar 18%.
Over het bedrijf Antengene Corporation Limited, een biofarmaceutisch bedrijf, houdt zich bezig met de ontwikkeling van nieuwe oncologische therapieën in Groot-China en internationaal. De gecommercialiseerde activa van het bedrijf omvatten ATG-010 (selinexor), een orale SINE-verbinding voor de behandeling van verschillende hematologische maligniteiten en vaste tumoren, waaronder recidief/refractair multipel myeloom (rrMM), recidief/refractair diffuus groot B-cel lymfoom en multipel myeloom (MM) bij volwassen patiënten op het Chinese vasteland, in Singapore, Australië, Hong Kong, Macau en Taiwan. Haar productkandidaten in een laat stadium omvatten ATG-008 (onatasertib), een mTOR-kinaseremmer voor de behandeling van baarmoederhalskanker en andere vergevorderde vaste tumoren.
Meer tonen Antengene Corporation Limited Samenvatting Hoe verhouden de winst en inkomsten van Antengene zich tot de beurswaarde? 6996 fundamentele statistieken Marktkapitalisatie HK$428.05m Inkomsten(TTM ) -HK$564.33m Inkomsten(TTM ) HK$59.75m
7.2x P/S-verhouding
-0.8x Koers/Winstverhouding Inkomsten en omzet Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM) 6996 resultatenrekening (TTM ) Inkomsten CN¥56.07m Kosten van inkomsten CN¥8.50m Brutowinst CN¥47.57m Overige uitgaven CN¥577.09m Inkomsten -CN¥529.52m
Laatst gerapporteerde inkomsten
Jun 30, 2024
Volgende inkomensdatum
n.v.t.
Winst per aandeel (EPS) -0.78 Brutomarge 84.84% Nettowinstmarge -944.43% Schuld/Eigen Vermogen Verhouding 18.1%
Hoe presteerde 6996 op de lange termijn?
Bekijk historische prestaties en vergelijking
Bedrijfsanalyse en status van financiële gegevens Gegevens Laatst bijgewerkt (UTC-tijd) Bedrijfsanalyse 2024/12/23 08:19 Aandelenkoers aan het einde van de dag 2024/12/20 00:00 Inkomsten 2024/06/30 Jaarlijkse inkomsten 2023/12/31
Gegevensbronnen De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC . De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
Pakket Gegevens Tijdframe Voorbeeld Amerikaanse bron * Financiële gegevens bedrijf 10 jaar Resultatenrekening Kasstroomoverzicht Balans Consensus schattingen analisten +3 jaar Financiële prognoses Koersdoelen analisten Marktprijzen 30 jaar Aandelenprijzen Dividenden, splitsingen en acties Eigendom 10 jaar Top aandeelhouders Handel met voorkennis Beheer 10 jaar Leiderschapsteam Raad van bestuur Belangrijkste ontwikkelingen 10 jaar
* voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige regelgevingsformulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Lees hier meer.
Analysemodel en Snowflake Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina . We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube .
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op .
Bronnen van analisten Antengene Corporation Limited wordt gevolgd door 7 analisten. 2 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
Analist Instelling Ziyu He China International Capital Corporation Limited Wangbin Zhou Citigroup Inc Ruili Bian Citigroup Inc
Toon 4 meer analisten 
